Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.